As you start your treatment, you may have questions about endometrial cancer, your treatment plan, and IMFINZI + chemotherapy.* To help learn the answers to some of these questions, check out the frequently asked questions below. Remember, your doctor is the best resource for answering specific questions about your treatment.
You are about to enter the IMFINZIHCP.com site for healthcare professionals.
The information on this site is intended for US healthcare professionals only.
Endometrial Cancer
IMFINZI FAQs
Get your questions about IMFINZI and chemotherapy* answered
*Carboplatin and paclitaxel.
Close All
Endometrial cancer (EC) is a type of cancer that starts in the inner lining of the uterus, called the "endometrium." When EC is advanced (Stage III or IV), the cancer has spread outside the uterus to sites such as the lymph nodes, pelvis, vagina, bladder, or liver. When it is recurrent, it means that EC that was treated before has now returned.
A biomarker is a measurable sign of normal or abnormal processes, conditions, or diseases. Mismatch repair (MMR) status is an important biomarker of endometrial cancer. An MMR status test is a type of biomarker test that screens for MMR deficiency. Your doctor will order this biomarker test so that, together, you can determine an appropriate treatment plan based on your MMR status. Knowing your MMR status is important because deficient MMR (dMMR) cancers may be treated with a type of medicine called "immunotherapy."
Close All
IMFINZI is a type of immunotherapy treatment used with chemotherapy* to treat advanced or recurrent endometrial cancer that is deficient mismatch repair (dMMR). IMFINZI may cause the immune system to attack healthy cells.
*Carboplatin and paclitaxel.
An immunotherapy is a type of cancer treatment that works with the immune system to find and attack cancer; immunotherapies may also attack healthy cells.
Chemotherapy* attacks all fast-growing cells, including cancer cells. Immunotherapy works with the immune system to find and attack cancer. IMFINZI and chemotherapy* may also affect healthy cells.
*Carboplatin and paclitaxel.
Close All
IMFINZI is an intravenous (IV) infusion given at your doctor’s office or an infusion center. If your doctor prescribes IMFINZI in combination with chemotherapy* to treat your advanced or recurrent dMMR endometrial cancer, you will be given this combination for 6 cycles of your treatment before receiving IMFINZI alone. For these cycles during which you receive IMFINZI and chemotherapy*, you will receive IMFINZI first followed by chemotherapy* on the same day.
*Carboplatin and paclitaxel.
The number of treatments will be determined by your doctor, depending on the condition of your cancer. You will stop receiving IMFINZI if your cancer progresses or if side effects become intolerable.
While on IMFINZI, you may experience side effects. This is because IMFINZI can cause your immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.
IMFINZI may also cause serious side effects. They include:
- Lung problems
- Intestinal problems
- Liver problems
- Hormone gland problems
- Kidney problems
- Skin problems
- Pancreas problems
- Problems in other organs
- Severe infusion reactions
- Rejection of a transplanted organ or tissue
- Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic)
The most common side effects of IMFINZI include:
- Inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs
- Muscle or bone pain
- Nausea
- Hair loss
- Feeling tired
- Stomach (abdominal) pain
- Constipation
- Rash
- Decreased level of magnesium in the blood
- Increased liver function tests
- Diarrhea
- Vomiting
- Cough
- Decreased level of potassium in the blood
- Shortness of breath
- Headache
- Increased level of alkaline phosphatase in the blood
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
*Carboplatin and paclitaxel.
Learn common terms for your treatment
See glossaryMinimize
Important Safety Information
What is the most important information I should know about IMFINZI® (durvalumab)?
What is the most important information I should know about IMFINZI?
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to...
Read full Important Safety InformationWhat is IMFINZI?
IMFINZI is a prescription medicine that is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat adults with a type of uterine cancer called endometrial cancer that has...
Important Safety Information
What is the most important information I should know about IMFINZI® (durvalumab)?
IMFINZI is a medicine that may treat certain cancers by working with your immune system. IMFINZI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.
What is IMFINZI?
IMFINZI is a prescription medicine that is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat adults with a type of uterine cancer called endometrial cancer that has spread (advanced) or has come back (recurred), and a laboratory test shows that your tumor is mismatch repair deficient (dMMR).
It is not known if IMFINZI is safe and effective in children.
Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:
Lung problems: cough, shortness of breath, and chest pain
Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness
Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), dark urine (tea colored), and bleeding or bruising more easily than normal
Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; and changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
Kidney problems: decrease in your amount of urine, blood in your urine, swelling of your ankles, and loss of appetite
Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in mouth or nose, throat, or genital area; fever or flu-like symptoms; and swollen lymph nodes
Pancreas problems: pain in your upper stomach area (abdomen), severe nausea or vomiting, and loss of appetite
Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with IMFINZI. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: Chest pain, irregular heartbeats, shortness of breath or swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling, numbness or weakness of the arms or legs; double vision, blurry vision, sensitivity to light, eye pain, changes in eye sight; persistent or severe muscle pain or weakness, muscle cramps, joint pain, joint stiffness or swelling; and low red blood cells and bruising
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, and back or neck pain
Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had
Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with IMFINZI. Your healthcare provider will monitor you for these complications
Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with IMFINZI. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects
Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you:
- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ or tissue transplant, including corneal transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. IMFINZI can harm your unborn baby
Females who are able to become pregnant:- Your healthcare provider will give you a pregnancy test before you start treatment with IMFINZI.
- You should use an effective method of birth control during your treatment and for 3 months after the last dose of IMFINZI. Talk to your healthcare provider about birth control methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with IMFINZI.
- are breastfeeding or plan to breastfeed. It is not known if IMFINZI passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of IMFINZI.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of IMFINZI?
IMFINZI can cause serious side effects (see above).
The most common side effects of IMFINZI when used with carboplatin and paclitaxel in adults with endometrial cancer include inflammation of the nerves causing numbness, weakness, tingling or burning pain of the arms and legs; muscle or bone pain; nausea; hair loss; feeling tired; stomach (abdominal) pain; constipation; rash; decreased level of magnesium in the blood; increased liver function tests; diarrhea; vomiting; cough; decreased level of potassium in the blood; shortness of breath; headache; and increased level of alkaline phosphate in the blood.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMFINZI. Ask your healthcare provider or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects related to AstraZeneca products
. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call
1-800-FDA-1088.
What is IMFINZI?
IMFINZI is a prescription medicine that is used in combination with the chemotherapy medicines carboplatin and paclitaxel followed by IMFINZI alone to treat adults with a type of uterine cancer called endometrial cancer that has spread (advanced) or has come back (recurred), and a laboratory test shows that your tumor is mismatch repair deficient (dMMR).
It is not known if IMFINZI is safe and effective in children.
Please see Full Prescribing Information including Medication Guide for IMFINZI.
This product information is intended for US consumers only.
This product information is intended for US consumers only.
IMFINZI is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.
©2025 AstraZeneca. All rights reserved. US-89240; US-107166 Last Updated 12/25
